1-11 of 11
Pedro Marques Ramos
Close
Sort by
Journal Articles

Molecular Measurable Residual Disease (MRD) Clearance (≤1%) Is Associated with Improved Clinical Outcomes in Patients with Higher-Risk Myelodysplastic Neoplasms (HR-MDS): An Exploratory Analysis of Stimulus-MDS1 in Patients Receiving Sabatolimab or Placebo + Hypomethylating Agent (HMA)

Amer M. Zeidan, Pierre Fenaux, Xia Han, David A. James, Kamel Malek, Pedro Marques Ramos, Yasushi Miyazaki, Uwe Platzbecker
Journal: Blood
Blood (2023) 142 (Supplement 1): 3236.
https://doi.org/10.1182/blood-2023-180765
Published: 2023
Journal Articles

Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

Amer M. Zeidan, Kiyoshi Ando, Odile Rauzy, Mehmet Turgut, Ming-Chung Wang, Roberto Cairoli, Hsin-An Hou, Yok-Lam Kwong, Montserrat Arnan Sangerman, Stef Meers, Vinod A. Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Jiaying Lyu, Pedro Marques Ramos, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker
Journal: Blood
Blood (2022) 140 (Supplement 1): 2063–2065.
https://doi.org/10.1182/blood-2022-158612
Published: 2022
Journal Articles

Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS)

Amer M. Zeidan, Amy E. DeZern, Uma Borate, Krissy Kobata, Susan E. Ide, John Sabo, Pedro Marques Ramos, Haiying Sun, Roger M. Lyons, Guillermo Garcia-Manero
Journal: Blood
Blood (2022) 140 (Supplement 1): 4069–4070.
https://doi.org/10.1182/blood-2022-167259
Published: 2022
Journal Articles

Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)

Valeria Santini, Uwe Platzbecker, Pierre Fenaux, Aristoteles Giagounidis, Yasushi Miyazaki, Mikkael A. Sekeres, Zhijian Xiao, Guillermo Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Pedro Marques Ramos, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 1340–1342.
https://doi.org/10.1182/blood-2022-160282
Published: 2022
Journal Articles

Best Practices for Validation of Measurable Residual Disease Assessments By Multiparameter Flow Cytometry in Emerging Clinical Trials of Acute Myeloid Leukemia

Pavinder Kaur, Anil Pahuja, Kevin Nguyen, Pedro Marques Ramos, PhD, Ling Du, PhD, Jacqueline J Cloos, Maaike E Heidinga, Yvonne J.M Oussoren-Brockhoff, Angele Kelder, Xun Li, Sarah Larson, MD, Shabnam Tangri, Ghanashyam Sarikonda, Naveen Dakappagari
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-137787
Published: 2020
Journal Articles

Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling

Ujunwa Cynthia Okoye-Okafor, MS,PhD, Komal Kumar Javarappa, PhD, Dimitrios Tsallos, BSc(Hons),MSc, Joseph J Saad, MSc, BSc, Lumie Benard, Victor Thiruthuvanathan, M.S, Sally Cole, Madhuri Tatiparthy, M.S., Stephen Ruiz, B.Sc, Stefanie DeFronzo, Celine Pallaud, PhD, Pedro Marques Ramos, PhD, Amit Verma, MBBS, Aditi Shastri, MD, Caroline A Heckman, PhD, Britta Will, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1280.
https://doi.org/10.1182/blood-2019-131461
Published: 2019
Journal Articles

Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia

Clinical Trials & Observations
Michael Dickinson, Honar Cherif, Pierre Fenaux, Moshe Mittelman, Amit Verma, Maria Socorro O. Portella, Paul Burgess, Pedro Marques Ramos, Jeea Choi, Uwe Platzbecker
Journal: Blood
Blood (2018) 132 (25): 2629–2638.
https://doi.org/10.1182/blood-2018-06-855221
Published: 2018
Includes: Supplemental data
Journal Articles

Eltrombopag Promotes Megakaryocyte Survival and Signaling in the Presence of Specific Cytotoxic Agents

Komal Kumar Javarappa, PhD, Dimitrios Tsallos, BSc(Hons), MSc, Bulat Zagidullin, MSc, Joseph J Saad, MSc, BSc, Jing Tang, PhD, Pedro Marques Ramos, PhD, Celine Pallaud, PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3836.
https://doi.org/10.1182/blood-2018-99-118449
Published: 2018
Journal Articles

Expanding the Utility of Midostaurin in Acute Myeloid Leukemia - Predictive Mutational Signatures in Patient Samples without FLT3 mutations and Clinically Applicable Synergistic Drug Combinations

Markus Vaha-Koskela, PhD, Muhammad Ammad-ud-din, PhD, Kirsi Siivola, MSc, Tanja Ruokoranta, MSc, Laura Turunen, PhD, Kimmo Porkka, MD PhD, Pedro Marques Ramos, PhD, Celine Pallaud, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2743.
https://doi.org/10.1182/blood-2018-99-116391
Published: 2018
Journal Articles

Quantitative Multiplex Immunohistochemistry Identifies Immunosuppression in the AML Bone Marrow and NK-Cells As Prognostic Biomarker in Intermediate-Risk Patients

Oscar Brück, MD, Olli Dufva, Sami Blom, MSc, Riku Turkki, MSc, Mette Ilander, PhD, Sanna M. Siitonen, MD PhD, Panu Kovanen, MD PhD, Celine Pallaud, PhD, Pedro Marques Ramos, PhD, Hanna Lähteenmäki, Katja Välimäki, Antonio Ribeiro, BSc, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Teijo Pellinen, PhD, Satu Mustjoki, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2774.
https://doi.org/10.1182/blood-2018-99-116628
Published: 2018
Journal Articles

Pre-Clinical Modeling of Concomitant Therapy with Azacytidine and Eltrombopag in MDS/AML

Sally Cole, Lumie Benard, Luis A. Carvajal, PhD, Amit Verma, MD, Ulrich G. Steidl, MDPhD, Pedro Marques Ramos, PhD, Celine Pallaud, PhD, Britta Will, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2950.
https://doi.org/10.1182/blood.V130.Suppl_1.2950.2950
Published: 2017